Metastatic breast cancer indication to be pursued for (Z)-endoxifen
Dr. Steven Quay, Chairman and Chief Executive Officer of Atossa Therapeutics, stated: “Our decision to advance (Z)-endoxifen into a metastatic breast cancer indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease. The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients who have exhausted other treatment options. By pursuing this strategy, we believe we are not only addressing an urgent medical need but also fortifying the path forward for expanding (Z)-endoxifen’s role across the full spectrum of breast cancer prevention and treatment. We look forward to providing future updates as we execute this plan.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.